UNSPSC 51282806: Dimetridazole

This classification denotes an antiprotozoal agent with the molecular formula C5H7N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K59P7XNB8X, chemically known as 1,2-dimethyl-5-nitroimidazole but generally known as dimetridazole, which bears US NIH Compound Identifier 3090. European Medicines Agency schedules Dimetridazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07183MIG. The term DIMETRIDAZOLE is an International Non-Proprietary Name.

UNSPSC 51282806 Dimetridazole is a Commodity code whose recent state and local posting activity shows significant mismatch with its nominal scope. The four recent opportunities tagged to this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which are dimetridazole or closely related veterinary or pharmaceutical compounds. The actual solicitations under this code reflect broader procurement for emergency medical supplies, pharmacy benefit programs, and pharmaceutical products across multiple therapeutic classes and distribution channels, suggesting either tagging error or an overly broad internal classification that does not align with the chemical specificity the code's name implies.

State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, municipal fire departments, and multi-state cooperative purchasing alliances. Recent activity spans Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023); the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription programs, due April 3, 2026); the City of Tampa (IFB for medical and first aid supplies for the Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000); and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026). Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon. The code shows limited relevance to dimetridazole procurement specifically; business development professionals should verify whether opportunities actually align with dimetridazole supply or whether this code assignment reflects upstream data quality issues in the source jurisdictions' procurement systems.